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Objective: To estimate recurrence rates of SCAs after primary treatment (surgery followed, or not, by radiotherapy) and recurrence rate ratios (RRRs) between SCAs and other NFPA subtypes.
Methods: A systematic review of published literature reporting on SCA outcomes up to 31 October 2017 was conducted. Recurrence rates, RRRs, and 95% CIs estimated from each study were pooled using a random-effects meta-analysis model.
Results: For determination of SCA recurrence rates, 14 studies (n = 297 patients) were selected; the recurrence rate was 5.96 (95% CI, 4.3 to 7.84) per 100 person-years. Based on studies with mean follow-up of ,5 or $5 years, 25% (cumulative incidence, 0.25; 95% CI, 0.13 to 0.38) and 31% (cumulative incidence, 0.31; 95% CI, 0.23 to 0.40) of SCAs had recurrence, respectively. Recurrence rates after surgery or surgery and radiotherapy were 5.41 (95% CI, 3.28 to 7.96) and 4.88 (95% CI, 0.67 to 11.54) cases per 100 person-years, respectively. Analysis of 10 eligible studies (n = 244 SCAs; n = 1622 NFPAs) showed no significant RRR (1.44; 95% CI, 0.9-2.33, P 5 0.130) between the groups. Focus on tumors treated solely by surgery also revealed no significant RRR (1.17; 95% CI, 0.79-1.75, P 5 0.429). (2) (3) (4) . In contrast to Cushing disease, which is mostly attributed to microadenomas, SCAs are diagnosed when they are large enough to cause pressure effects to surrounding structures, necessitating surgical resection, ultimately leading to their pathological diagnosis (5, 6) .
Traditionally, SCAs have been considered aggressive lesions and, based on the 2017 World Health Organization Classification of Pituitary Tumors, they are recognized as "high-risk pituitary adenomas" (3); this concept has mostly relied on studies reporting higher recurrence rates compared with other subtypes of NFPA (7) (8) (9) (10) (11) , potentially leading for low threshold decisions on offering early adjuvant radiotherapy (RT). On the other hand, a number of series have not confirmed this finding (12) (13) (14) (15) (16) (17) (18) (19) , supporting the view that imaging follow-up and RT protocols at initial presentation should not differ from those adopted for other NFPA subtypes. These points, combined with the small number of cases included in each study (even in those from large pituitary centers), due to the rarity of this adenoma subtype, and the differences in the follow-up duration between SCAs and other NFPAs within the same study (8, 10) suggest that robust evidence on the long-term clinical behavior of SCAs after primary treatment is still lacking.
To elucidate these controversial data and address this topic reliably, we conducted a systematic review and meta-analysis of published literature reporting on outcomes of SCAs. Our first aim was to estimate the recurrence rates of SCAs after surgery followed or not by adjuvant RT, and our second objective was to clarify if SCAs carry a higher risk of recurrence after primary treatment compared with other subtypes of NFPAs.
Methods
The systematic review and meta-analysis were conducted on the basis of an a priori protocol, registered on PROSPERO (an international database of prospectively registered systematic reviews; registration no. CRD42017053862). The methods and results of the review are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement (20) .
Search strategy and eligibility criteria
A systematic search of Medline, Embase and Cochrane Library Central databases was conducted to identify relevant articles published up to 31 October 2017. A detailed search strategy was developed by the study investigators with input from an information specialist; details are provided in an online repository (21) . The reference lists of all retrieved articles were also included in the literature research and citation tracking. Only articles published in English were included; duplicate studies and those with overlapping populations were excluded. Two independent reviewers (A.F. and A.L.) screened the initial search results for titles and abstracts pertaining to the research questions and then performed a full-text assessment of the potentially eligible published studies. Discrepancies in reviewers' selections were resolved through discussion and consensus with a third reviewer (N.K.). Eligible studies were randomized controlled, nonrandomized controlled, prospective and retrospective cohort, case-control, and case series (with at least five cases) reporting on recurrence or regrowth rates of SCAs. Review articles, letters, commentaries, and meeting abstracts were excluded. For the first review question, eligible studies were those including human subjects with SCA treated primarily by surgery followed or not by adjuvant RT. For the second review question, eligible studies were those comparing outcomes of human subjects with SCA ("exposed" cohort) with other subtypes of NFPA ("unexposed" cohort) treated primarily by surgery followed or not by adjuvant RT. Any article was excluded (1) if it did not report recurrence/regrowth rates, and (2) if imaging follow-up was unknown or less than 6 months. Recurrence/regrowth was defined as radiological progress of the tumor (i.e., increase in size of residual tumor or regrowth of adenoma when previously no residual tumor mass was present).
Data extraction
Data from the selected studies were extracted independently by two investigators (A.F. and A.L.). The information extracted from each article included first author and year of publication, comparison group (i.e., patients with other subtypes of NFPA), number of patients in each cohort, age at diagnosis of the adenoma, follow-up duration, and recurrence rates (in crude numbers and as a proportion). Data are also presented separately for two subgroups of patients: those treated and those not treated with adjuvant RT.
Risk of bias assessment
The Newcastle-Ottawa Scale was used for evaluation of risk of bias of all included observational studies (22) . Reviewers assessed independently the selection of studies, as well as the comparability and their outcomes using a rated system-low, moderate, and high risk-depending on the scoring for each section as presented in Newcastle-Ottawa Scale assessment. Comparability of studies on the basis of adjuvant RT, extent of tumor removal, and length of follow-up was the main area of focus. Any scoring discrepancies were resolved through combined reassessment and consensus by all authors.
Statistical analysis
We conducted a meta-analysis using the random-effects model described by DerSimonian and Laird (23) to pool incidence rates and recurrence rate ratios (RRRs) and their 95% CIs. The random-effects model was chosen to account for heterogeneity across the included studies. For pooling recurrence rates, we performed Freeman-Turkey double arcsine transformation to address variance instability (24, 25) . When pooling RRRs, a fixed-continuity correction of 0.1 was used in case a study had no outcome in one of the arms (26) . Statistical heterogeneity was tested by the Q statistic, generated from the x 2 test, in which P , 0.10 was considered significant. Heterogeneity was further quantified through the I 2 measure, with values between 0% and 30% indicating no important heterogeneity, between 30% and 60% indicating moderate heterogeneity, between 60% and 75% indicating substantial heterogeneity, and between 75% and 100% indicating considerable heterogeneity (27) . I 2 and P values of statistical heterogeneity were given for all analyses. All statistical analyses were performed using Stata, version 14.0 (StataCorp, College Station, TX).
For both outcomes (i.e., recurrence rates of SCAs and risk of recurrence of SCAs compared with other subtypes of NFPAs) of the meta-analysis, we estimated pooled incidence rates and RRRs with their 95% CIs. Because of significant variations in the length of follow-up between the included studies, we also conducted analysis accounting for duration of follow-up, and we reported recurrence rates per 100 person-years. In addition, we performed a subgroup analysis estimating recurrence rates separately for patients with follow-up of less or more than 5 years.
Results

Study identification and description
The systematic search identified 1942 potentially eligible articles. After screening and assessment of eligibility, 14 articles were eligible for the first review question (8-10, 12, 13, 15-18, 28-32) and 10 for the second review question (8-10, 12, 13, 15-18, 29) . All included studies were observational. The complete study selection process is described in Fig. 1 .
For the calculation of the recurrence rates of SCAs, 297 patients with mean follow-up between 2 and 7.4 years were included. For the assessment of the risk of recurrence of SCAs compared with other subtypes of NFPAs, 244 patients with SCAs followed for mean periods between 2 and 7.4 years were compared with 1622 patients with other NFPA subtypes with mean follow-up of between 2 and 6.3 years. A summary of the included studies is given in Table 1 .
Data on recurrence in patients with SCA treated only by surgery were extracted from 10 studies (8, 12, 13, 15, 17, 18, 28, (30) (31) (32) and in those offered adjuvant RT from four studies (13, 15, 28, 32) ; these data are provided in an online repository (21) . For this subgroup analysis, four studies listed in Table 1 had to be excluded, three because the impact of adjuvant RT was not assessed separately (9, 10, 16) and one because administration of adjuvant RT was unknown (29) .
Risk of bias
All but one study contributing data to answer the first question of the meta-analysis had low risk of bias (one had moderate risk of bias) (21) . Studies contributing data to answer the second question of the meta-analysis were at moderate risk of bias (21) .
Recurrence rates of SCAs
Overall, the recurrence rate of SCAs was 5. (Fig. 2b) . Given the variable follow-up duration of the patients with SCA in the included articles, recurrence incidences were estimated in two groups: those with mean follow-up ,5 years or $5 years. In the studies that contributed with follow-up ,5 years (n = 8 studies), 25% of the patients had tumor recurrence (cumulative incidence, 0.25; 95% CI, 0.13 to 0.38; I 2 = 60.54%, P = 0.01), whereas in the studies with follow-up $5 years (n = 6 studies), 31% of patients had tumor recurrence (cumulative incidence, 0.31; 95% CI, 0.23 to 0.400; I 2 = 0.00%, P = 0.48) (Fig. 3a) .
After stratifying the studies for adjuvant RT and length of follow-up, recurrence was detected in 22% (cumulative incidence, 0.22; 95% CI, 0.03 to 0.50) of the patients treated only by surgery and followed-up for ,5 years (n = 5 studies; I 2 = 76.91%, P = 0.00) and in 31% (cumulative incidence, 0.31; 95% CI, 0.21 to 0.42) of those treated only by surgery and followed-up for $5 years (n = 5 studies; I 2 = 0.36%, P = 0.40) (Fig. 3b) . There was only one study with data on SCAs treated with adjuvant RT and followed-up for ,5 years (28); recurrence in four of six patients was reported in that study. Furthermore, three studies had data on the outcomes of patients who underwent tumor irradiation and were followed-up for $5 years (13, 15, 32), but the number of patients was too low (n = 14) to allow meta-analysis; among these 14 patients, three had SCA recurrence.
Risk of recurrence of SCAs compared with other subtypes of NFPAs
In our meta-analysis, there was no significant difference in the recurrence rates between SCAs and other subtypes of NFPAs (RRR, 1.44; 95% CI, 0.90 to 2.33, P = 0.13; I 2 = 64.1%, P = 0.003; Fig. 4a ). Similarly, no significant difference was found when tumors not treated with adjuvant RT were compared (RRR, 1.17; 95% CI, 0.79 to 1.75, P = 0.43; I 2 = 9.3%, P = 0.357; Fig. 4b ). Only one article included SCAs and other subtypes of NFPAs that had received adjuvant RT (15) . In that study, recurrences were detected in two of six SCAs and in four of 20 other NFPAs (mean follow-up, 5.2 and 4.2 years, respectively).
Discussion
In this systematic review and meta-analysis, we assessed the recurrence rates of SCAs and their risk of recurrence compared with other subtypes of NFPAs. We found that overall, the recurrence rate of SCAs was 5.96 cases per 100 person-years and, based on studies with mean follow-up $5 years, 31% of the patients had tumor recurrence. Furthermore, after accounting for length of follow-up, our meta-analysis showed that the RRR between SCAs and other subtypes of NFPAs was not significant. This was also confirmed when the comparison focused on tumors that were not treated with adjuvant RT after primary surgery.
Among NFPAs, the group of SCAs has attracted considerable attention because of the traditional concept that they demonstrate a more aggressive clinical behavior and because they can evolve into Cushing disease after long intervals of inactivity. The mechanisms of SCA genesis and growth are poorly understood and studies assessing their postoperative outcomes are limited, having wide variations in the reported recurrence rates (5, 33) . This may be attributed to differences in the duration of followup, small sample size, review of irradiated and nonirradiated cases together, and inclusion of recurrent tumors in the analysis. To overcome these limitations, we used strict inclusion and exclusion criteria, focusing on cases after primary surgical treatment (combined or not with adjuvant RT) and taking into account the length of follow-up. We also excluded two patients from the Lopez et al. series (30) because of uncertainty about the diagnosis of SCA (both had temporary postoperative adrenal insufficiency and one patient had Cushing phenotype, as well), and two patients from the Alahmadi et al. study (12) , because of the presence of double adenomas (with ACTH and growth hormone staining).
Recurrence rates were 4.88 (95% CI, 0.67 to 11.54) and 5.41 (95% CI, 4.10 to 7.49) cases per 100 person-years with or without adjuvant RT, respectively, with moderate heterogeneity between studies. It is generally accepted that RT is beneficial for long-term NFPA control after surgery (34, 35) ; however, this treatment modality does not prevent tumor regrowth in all patients (36) . Notably, the outcomes of SCAs after adjuvant RT were reported in only four studies (13, 15, 28, 32) and direct comparison between the irradiated and nonirradiated groups leading to robust conclusions was not possible. Thus, Bradley et al. (13) , in a series of 28 patients (one of whom died during the postoperative period and was excluded from our analysis), reported recurrence rates of 36% in the patients who did not undergo irradiation and 20% in those who did (mean follow-up, 7.4 years); Webb et al. (32) , in a study of 22 patients, reported recurrence rates of 26% and 0% in patients who did not undergo irradiation and those who did, respectively (mean follow-up, 6.1 years). On the other hand, Baldeweg et al. (28) , in a series of 15 cases, reported 11% and 67% recurrence rates in the nonirradiated and irradiated patients, respectively (mean follow up 4.8 years), and in a study of 28 SCAs, Cho et al. (15) found tumor progression in 23% and 33% of patients who did not undergo irradiation and those who did, respectively (mean follow-up, 5.2 years).
Most NFPA recurrences are detected in the first 5 postoperative years (37, 38) . After stratifying the studies for modality of primary treatment and duration of follow-up, we found that in the group treated solely by surgery, recurrence was diagnosed in 22% of the patients monitored for ,5 years (considerable heterogeneity between studies) and in 31% of those followed for $5 years (no heterogeneity among studies). The limited sample size of patients treated with surgery and adjuvant RT did not allow solid determination of the recurrence rates stratified for follow-up duration in this group; additional studies are required to elucidate this issue. Interestingly, our meta-analysis did not confirm that SCAs have higher recurrence rates than the other NFPA subtypes (RRR, 1.44; 95% CI, 0.9 to 2.33). Focus on reports with patients offered only surgery supported the same view (RRR, 1.17; 95% CI, 0.79 to 1.75), with no important heterogeneity among the studies. In the only available article including patients with both types of adenomas who had been offered adjuvant RT, recurrence rates were 33% for SCAs and 20% for other NFPAs during mean observation periods of 5.2 and 4.2 years, respectively (15) . In that study, conventional fractionated RT was used in 67% of SCAs and 50% of NFPAs, and gamma knife radiosurgery was offered to 33% and 50% of SCAs and NFPAs, respectively; the radiation therapy protocol and the latency time between surgical treatment and adjuvant therapy did not differ between the two groups (15). Langlois et al. (10) found higher adenoma progression rates in a series of 39 SCAs compared with 70 silent gonadotroph adenomas (36% vs 10%; P = 0.001). It should be noted, however, that in the latter group, follow-up was significantly shorter (mean, 6.7 vs 2.7 years). Similar results were also reported in the cohort of Jahangiri et al. (9) , with 27% of SCAs recurring compared with 7% of NFPAs (P , 0.001); nonetheless, mean follow-up was short (2.4 and 3.1 years, respectively). On the other hand, in studies with similar follow-up length between the two groups (12, 15, 16) , no difference in the recurrence rates was detected.
Although we did not find in our meta-analysis evidence supporting an important increase in risk of recurrence of SCAs compared with other NFPA subtypes, an area potentially raising concern about the prognosis of these tumors is the reported aggressive course of a subset of recurrent SCAs (13, 15, 32) , which continued to show multiple growths requiring various treatment modalities; however, not all series support these findings (9, 16) . Nonetheless, the number of these cases is extremely small and identification of predictive factors in a reliable way is currently not possible. It is of note that in a study by Ioachimescu et al. (16) comparing SCAs with other NFPA subtypes, there was no significant difference in the percentage of patients requiring multiple surgeries and RT. Furthermore, malignant transformation of SCAs has been described and this may also be seen in cases with gain in hormone secretion and development of overt Cushing syndrome (2, 5, 39, 40) . In a recent review of all published cases of malignant NFPAs, staining for ACTH was reported in nine out of 38 patients (23.7%) (41); again, the very small number of total cases makes the interpretation of this rate difficult. Therefore, it would be reasonable to consider that decisions on the management strategies for the total group of SCAs should not rely on the outcomes of these rare subgroups of aggressive SCAs.
Potential sources of heterogeneity in our meta-analysis include the variable sample size and follow-up duration of patients between different studies and between groups under comparison within the same study, as well as variations in the RT techniques and protocols and in the extent of tumor removal and location of residual tumor after primary surgery [which has been reported as a factor predicting recurrence risk in NFPAs (17, 42, 43) ].
The strengths of our study include the comprehensive literature search, the strict protocol-driven selection of studies, the duplicate process for study selection and evaluation, and the performance of analyses also taking into account the length of follow-up. Limitations include the retrospective, observational nature of the available reports, the moderate to substantial heterogeneity in the metaanalysis of a number of outcomes, the absence of data on pathological or molecular markers of aggressiveness, and the small number of patients offered adjuvant RT, which did not allow sound estimation of outcomes in this subgroup. Finally, given that transcription factor expression analysis was not available, the possibility of inclusion of corticotroph adenohypophyseal cell differentiation tumors in the group of "null cell" NFPAs cannot be excluded. Nonetheless, based on a recent report (44) , it is anticipated that only a small proportion of hormone-immunonegative adenomas express corticotroph lineage-specific transcription factors; future studies will elucidate this field.
In conclusion, our systematic review and meta-analysis of studies of moderate risk of bias did not confirm higher risk of SCA recurrence compared with that of other NFPA subtypes. Our data indicate the need for additional methodologically robust studies (i.e., adequately powered, with appropriate adjustment for all possible confounding factors and of prolonged follow-up) to compare SCAs with other NFPA subtypes and clarify their true biological behavior, and to determine whether they, indeed, should be classified as high-risk pituitary adenomas (per the 2017 World Health Organization recommendation). Furthermore, studies particularly looking at the rare subgroups of SCAs with multiple growths and resistance to various treatments, malignant transformation, or development of overt Cushing disease, aiming to shed light on their pathophysiology and factors predicting their prognosis, will be of major importance in the field and will facilitate the development of valuable evidence-based management protocols in the area of pituitary neuroendocrine tumors.
